Literature DB >> 30624578

Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases.

Cristian Navarrete-Dechent1,2, Miguel Cordova1, Michael A Postow3,4, Melissa Pulitzer5, Cecilia Lezcano5, Allan C Halpern1, Anthony M Rossi1,4.   

Abstract

Importance: Melanoma incidence and the use of systemic treatments for it are rising. Current treatment monitoring uses clinical examination and radiologic examinations; however, cutaneous involvement and cutaneous metastasis may not be well visualized. Reflectance confocal microscopy (RCM) is a US Food and Drug Administration-approved, noninvasive technology that enables visualization of the skin with quasihistological resolution. Objective: To evaluate the feasibility of using RCM to monitor advanced melanomas treated with immunotherapy. Design, Setting, and Participants: This case report study took place from March 2017 to June 2018 and included 2 patients with locally advanced melanoma who were not candidates for surgery or were not willing to have surgery and who were started on an immunotherapy regimen at a tertiary care cancer hospital. Main Outcomes and Measures: Clinical and RCM findings correlated with histopathology.
Results: In the patients, locally advanced melanoma with cutaneous involvement was treated with immunotherapy (pembrolizumab in 1 patient and an ipilimumab-nivolumab combination in the other) with resulting clearance of the lesions. Use of RCM showed the disappearance of clear melanoma features seen at baseline; these findings correlated with histopathology. The response was not seen with radiologic images, such as magnetic resonance imaging and computed tomography. Conclusions and Relevance: Although RCM will not replace larger field imaging (such as magnetic resonance imaging, positron emission tomography, and computed tomography) in the management and follow-up of melanoma or other tumors, for imaging of cutaneous involvement and disease monitoring, RCM holds promise as a novel noninvasive technique.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30624578      PMCID: PMC6440283          DOI: 10.1001/jamadermatol.2018.3688

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  4 in total

1.  Reflectance confocal microscopy-guided carbon dioxide laser ablation of low-risk basal cell carcinomas: A prospective study.

Authors:  Cristian Navarrete-Dechent; Miguel Cordova; Konstantinos Liopyris; Oriol Yélamos; Saud Aleissa; Brian Hibler; Heidy Sierra; Aditi Sahu; Nina Blank; Milind Rajadhyaksha; Anthony Rossi
Journal:  J Am Acad Dermatol       Date:  2019-06-14       Impact factor: 11.527

2.  Optical imaging guided- 'precision' biopsy of skin tumors: a novel approach for targeted sampling and histopathologic correlation.

Authors:  Cristian Navarrete-Dechent; Miguel Cordova; Aditi Sahu; Ashfaq A Marghoob; Chih-Shan Jason Chen; Konstantinos Liopyris; Ayelet Rishpon; Curtis Chen; Milind Rajadhyaksha; Klaus J Busam
Journal:  Arch Dermatol Res       Date:  2020-08-25       Impact factor: 3.017

3.  Reflectance confocal microscopy terminology glossary for melanocytic skin lesions: A systematic review.

Authors:  Cristian Navarrete-Dechent; Konstantinos Liopyris; Jilliana Monnier; Saud Aleissa; Lindsay M Boyce; Caterina Longo; Margaret Oliviero; Harold Rabinovitz; Ashfaq A Marghoob; Allan C Halpern; Giovanni Pellacani; Alon Scope; Manu Jain
Journal:  J Am Acad Dermatol       Date:  2020-05-23       Impact factor: 11.527

4.  Curcumol inhibits the proliferation and metastasis of melanoma via the miR-152-3p/PI3K/AKT and ERK/NF-κB signaling pathways.

Authors:  Ning Ning; Sulai Liu; Xiehong Liu; Zeyu Tian; Yu Jiang; Nanhui Yu; Boyu Tan; Hao Feng; Xing Feng; Lianhong Zou
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.